Provided are an isolated binding protein including a pan-species-specific plasmodium lactate dehydrogenase antigen binding domain and a preparation method thereof. The antigen binding domain includes at least one complementarity determining region selected from a defined amino acid sequence, or has at least 80% of sequence identity with the complementarity determining region of the following amino acid sequence and an affinity of K.sub.D≤1.5647×10.sup.−9 mol/L with a pan-species-specific plasmodium lactate dehydrogenase, and may identify the pan-species-specific plasmodium lactate dehydrogenase. The binding protein may be applied to the field of detection of plasmodium lactate dehydrogenase proteins.

An in vitro method for diagnosis, prognosis, risk assessment, monitoring, therapy guidance and/or therapy control of an infectious disease, includes (a.) providing a sample of a subject exhibiting clinical symptoms of and/or suspected of having an infection, (b.) determining a level of D-lactate in said sample, (c.) in which the level of D-lactate is indicative of the presence of an infectious disease, characterized in that (d.) the level of D-lactate in said sample is determined by means of an electrochemical sensing system (biosensor). In embodiments, the electrochemical sensing system includes a potentiometric or an amperometric sensor. Preferably, the electrochemical system includes a D-lactate binding molecule, that is preferably immobilized on a detection (working) electrode. In embodiments, the detection electrode with the immobilized D-lactate binding molecule is included by a (disposable) test strip for insertion into a portable reader.

A system for determining a level of hematocrit includes a test strip configured to receive a sample; a meter configured to receive the test strip; and further including circuitry and a microprocessor, the circuitry and microprocessor configured to apply electrical energy to the test strip and the sample and determine an electrical property of the sample, either the impedance phase angle or the impendence magnitude of the test strip and the sample and, based on the electrical property, calculate the level of hematocrit in the sample.

The present invention provides a biomaterial assay strip as a strip-type platform for use in a point-of-care test device. The strip includes a porous matrix bearing micropores and composed of materials comprising a copolymer selected from the group comprising polysulfone, polyethersulfone, and polyarylsulfone in order to increase separation efficiency of the blood cells contained in a sample and to improve accuracy and reproducibility of measurements with a small amount of blood, wherein the matrix comprises an enzyme, a dye, and a hydrophilic polymer material therein, which all respond to a biomaterial and wherein the matrix develops a color as the biomaterial contained in the sample which is brought into contact with the upper layer of the matrix and then diffuses to the lower layer of the matrix, thereby assaying the biomaterial.

Provided herein are host cells or host cellular expression systems that express a membrane protein. Also, methods are provided that use such host cells or host cellular expression systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.

The present disclosure relates to methods of detecting and treating inherited neuropathy.

Biomarker detection sensors for detecting disease-specific biomarkers, kits based thereon, methods for determining disease-specific biomarkers in body fluids and uses are presented. The sensors include a substrate having bound thereon metal nanoparticles arranged in branched two-dimensional structures and/or a two-dimensional lattice, and anti-biomarker receptors bound to the metal nanoparticles.

There is provided a kit that is used for fractionation of cholesterol (lipoprotein C) in a lipoprotein other than small dense LDL in a sample, the kit containing a first reagent composition having at least one activity selected from the group consisting of a cholesterol esterase activity and a cholesterol oxidase activity and a second reagent composition for quantifying the lipoprotein C of a measurement target, where a ratio R1 represented by ABS400/ABS450 is 0.90 or more and 3.50 or less, and in an absorption spectrum after storing the second reagent composition at 37° C. for two weeks, the ratio R1 represented by ABS400/ABS450 is 0.90 or more and 9.00 or less.

This disclosure relates to methods and kits for determining the presence and/or amount of one or more analytes in a keratinized structure (e.g., hair) sample.

Process for in vitro diagnosis and/or monitoring and/or prognosis and/or theranosis of hepatic disorders from a biological sample originating from a subject, in which process the presence and/or the concentration of the marker ADH1B (SEQ ID NO.2) and/or the presence and/or the concentration of the combination of the markers ADH1B (SEQ ID NO.2) and ADH1A (SEQ ID NO.1) is determined.